Financial Data and Key Metrics Changes - The core business is expected to grow between 4%-7%, which aligns with the weighted average market growth rate of 4%-6% [6][8] - The company anticipates a short-term headwind due to three specific products not achieving the expected market adoption rate in 2026, impacting overall performance [7][15] - The stock is considered undervalued, with the fundamentals and core business remaining strong despite the current challenges [23][51] Business Line Data and Key Metrics Changes - The company focuses on fast-growing markets such as electrophysiology, neurovascular, structural heart, and neuromodulation, with 80% of the product development sales pipeline concentrated in these areas [4][5] - The electrophysiology portfolio has performed well over the past four to five years, although two specific products are facing adoption challenges [25][15] - The overall portfolio, excluding the impacted products, is still expected to grow at a strong double-digit rate [28] Market Data and Key Metrics Changes - The medical device market is experiencing significant innovation, particularly in electrophysiology and structural heart segments, which are expected to drive future growth [25][29] - The company has a global manufacturing footprint, which allows it to remain competitive despite potential tariff impacts [50][51] Company Strategy and Development Direction - The company aims to be the most innovative Contract Development and Manufacturing Organization (CDMO) in the world, focusing on building critical engineering and manufacturing capabilities [10][11] - The strategy includes targeted acquisitions to enhance capabilities and a strong emphasis on organic growth through innovative product launches [4][55] - The company is committed to maintaining operational efficiency through its Integer Production System, which focuses on lean manufacturing practices [39][40] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting to return to growth in the second half of 2026 and above-market growth in 2027 [8][61] - The company is confident in its strong pipeline and the ability to weather the current market pressures due to its diversified portfolio [17][63] - Management emphasizes the importance of customer relationships and market feedback in navigating product performance and demand [21][22] Other Important Information - A $200 million share repurchase program has been authorized, reflecting the board's confidence in the company's fundamentals and growth strategy [11][12] - The company has not previously engaged in share repurchase programs, indicating a strategic shift in capital allocation [12] Q&A Session Summary Question: What are the expectations for the company's growth in the coming years? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong core business [60][61] Question: How does the company plan to manage costs during the current air pocket? - The company will focus on generating gross margin expansion through lean manufacturing and will be disciplined in managing fixed costs during this period [39][40] Question: What is the company's approach to acquisitions? - The company is focused on tuck-in acquisitions that enhance critical capabilities rather than transformative acquisitions, which were more common in the past [55]

Financial Data and Key Metrics Changes - The core business is expected to grow between 4% to 7% in 2026, which aligns with the weighted average market growth rate of 4% to 6% [6] - The company anticipates a short-term headwind due to three specific products that are not achieving the expected market adoption rates in 2026, impacting growth [6][7] - The stock is considered undervalued by management, reflecting strong fundamentals and financial strength [10][20] Business Line Data and Key Metrics Changes - The product development sales pipeline is approximately 80% focused on the fastest-growing markets, indicating a strong growth trajectory [5] - The electrophysiology portfolio has been performing well, with significant growth over the past four to five years, despite current headwinds [22][25] - The company is diversifying its portfolio, with no single program representing more than a few percentage points of total revenues, which mitigates risk [15] Market Data and Key Metrics Changes - The medical device market is experiencing a phase of multiple new product iterations, indicating a dynamic environment for innovation [21] - The company is well-positioned in the medtech ecosystem, partnering with both large and emerging companies [3] Company Strategy and Development Direction - The strategy focuses on building differentiated capabilities through organic growth and targeted acquisitions to enhance product offerings [4] - The company aims to be the most innovative contract development and manufacturing organization (CDMO) in the world, emphasizing engineering expertise and manufacturing efficiency [9][10] - Future growth is expected to be driven by new product launches in the second half of 2026 and into 2027, with a strong pipeline of innovative therapies [39][55] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting a return to growth in the second half of 2026 and above-market growth in 2027 [8][20] - The company is committed to maintaining operational efficiency and managing costs during this period, focusing on areas that will drive future growth [36] - Management is optimistic about the strength of the pipeline and the potential for market recovery, emphasizing the importance of execution and quality [9][20] Other Important Information - The company has initiated a $200 million share repurchase program, reflecting confidence in its financial strength and strategy [10] - The global manufacturing footprint is designed to mitigate risks associated with tariffs and ensure cost competitiveness [43][47] Q&A Session Summary Question: What is the outlook for the company's growth in 2026 and beyond? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong pipeline [55][56] Question: How does the company manage costs during the current air pocket? - The company plans to focus on manufacturing efficiencies and be disciplined in managing fixed costs during this period [36] Question: What is the company's strategy regarding acquisitions? - The company is focused on tuck-in acquisitions to build critical capabilities rather than transformative acquisitions [49]